For instance, drugs targeting PIK3CA or MEK signals, such as alpelisib or trametinib, respectively, may theoretically offer a new treatment for women with endometriosis whose lesions have mutations in PIK3CA or KRAS [20]. This evidence concerns the gene KRAS and endometriosis.